{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:01Z","timestamp":1793330701360,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40262-022-01129-y","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T01:02:27Z","timestamp":1653958947000},"page":"819-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Filgotinib: A Clinical Pharmacology Review"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-5451","authenticated-orcid":false,"given":"Florence","family":"Namour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacey","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"1129_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/rheumatology\/keu430","volume":"54","author":"P Isomaki","year":"2015","unstructured":"Isom\u00e4ki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology (Oxford). 2015;54:1103\u201313. https:\/\/doi.org\/10.1093\/rheumatology\/keu430.","journal-title":"Rheumatology (Oxford)"},{"key":"1129_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrgastro.2017.138","volume":"14","author":"M Neurath","year":"2017","unstructured":"Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:688. https:\/\/doi.org\/10.1038\/nrgastro.2017.138.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1129_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"key":"1129_CR4","first-page":"1650","volume":"32","author":"JG Walker","year":"2005","unstructured":"Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32:1650\u20133.","journal-title":"J Rheumatol"},{"key":"1129_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521\u201346. https:\/\/doi.org\/10.1007\/s40265-017-0701-9.","journal-title":"Drugs"},{"key":"1129_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","volume":"13","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693\u2013703. https:\/\/doi.org\/10.1080\/1744666X.2017.1291342.","journal-title":"Expert Rev Clin Immunol"},{"key":"1129_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(16)32537-5.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"1129_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O'Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1129_CR9","doi-asserted-by":"publisher","first-page":"S602","DOI":"10.1016\/S0016-5085(17)32149-2","volume":"152","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Feagan BG, De Hertogh G, Chen G, French DF, Huntzicker EG, et al. Filgotinib (GLPG0634, GS-6034), a JAK-1 selective inhibitor, significantly reduces gut tissue PSTAT3 in Crohn\u2019s disease patients. Gastroenterology. 2017;152(Suppl 1):S602.","journal-title":"Gastroenterology"},{"key":"1129_CR10","unstructured":"Gilead Sciences. Jyseleca summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf. Accessed 9 Oct 2021."},{"key":"1129_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signaling by filgotinib, upadacitinib, tofacitinib, and baricitinib. Ann Rheum Dis. 2021;80:865\u201375. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219012.","journal-title":"Ann Rheum Dis"},{"issue":"10 Suppl","key":"1129_CR12","first-page":"S209","volume":"65","author":"R Galien","year":"2013","unstructured":"Galien R, Vayssiere B, De Vos S, Auberval M, Vandeghinste N, Dupont S, et al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients. Arthritis Rheum. 2013;65(10 Suppl):S209\u201310.","journal-title":"Arthritis Rheum"},{"key":"1129_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","volume":"54","author":"F Namour","year":"2015","unstructured":"Namour F, Diderichsen PM, Cox E, Vayssi\u00e8re B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIB dose selection. Clin Pharmacokinet. 2015;54:859\u201374. https:\/\/doi.org\/10.1007\/s40262-015-0240-z.","journal-title":"Clin Pharmacokinet"},{"key":"1129_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg J-E, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315\u201325. https:\/\/doi.org\/10.1001\/jama.2019.9055.","journal-title":"JAMA"},{"key":"1129_CR15","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848\u201358. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214.","journal-title":"Ann Rheum Dis"},{"key":"1129_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727\u201338. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219213.","journal-title":"Ann Rheum Dis"},{"key":"1129_CR17","doi-asserted-by":"publisher","unstructured":"Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8.","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"1129_CR18","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: Jyseleca. EMA\/424374\/2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jyseleca-epar-public-assessment-report_en.pdf. Accessed 4 Feb 2021."},{"key":"1129_CR19","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1021\/jm501262q","volume":"57","author":"CJ Menet","year":"2014","unstructured":"Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014;57:9323\u201342. https:\/\/doi.org\/10.1021\/jm501262q.","journal-title":"J Med Chem"},{"key":"1129_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cpdd.755","volume":"9","author":"K Anderson","year":"2020","unstructured":"Anderson K, Xin Y, Zheng H, Yun C, Kwan E, Qin A, et al. Filgotinib, a JAK1 inhibitor, has no effect on QT interval in healthy subjects. Clin Pharmacol Drug Dev. 2020;9:32\u201340. https:\/\/doi.org\/10.1002\/cpdd.755.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1129_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/cpdd.659","volume":"8","author":"K Anderson","year":"2019","unstructured":"Anderson K, Zheng H, Kotecha M, Cuvin J, Scott B, Sharma S, et al. The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8:585\u201394. https:\/\/doi.org\/10.1002\/cpdd.659.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1129_CR22","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","volume":"191","author":"L Van Rompaey","year":"2013","unstructured":"Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568\u201377. https:\/\/doi.org\/10.4049\/jimmunol.1201348.","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"1129_CR23","first-page":"331","volume":"78","author":"K Anderson","year":"2019","unstructured":"Anderson K, Zheng H, Medzihradsky O, Yizhao L, Qin A, Kearney B, et al. Pharmacokinetics and short-term safety of filgotinib, a selective Janus kinase 1 inhibitor, in subjects with moderate hepatic impairment. Ann Rheum Dis. 2019;78(Suppl 2):331.","journal-title":"Ann Rheum Dis"},{"key":"1129_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1872312810666151223103353","volume":"10","author":"F Namour","year":"2016","unstructured":"Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van't  Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10:38\u201348. https:\/\/doi.org\/10.2174\/1872312810666151223103353.","journal-title":"Drug Metab Lett"},{"key":"1129_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389200219666180821094502","volume":"20","author":"L Di","year":"2019","unstructured":"Di L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 2019;20:91\u2013102. https:\/\/doi.org\/10.2174\/1389200219666180821094502.","journal-title":"Curr Drug Metab"},{"key":"1129_CR26","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1111\/bcp.13726","volume":"84","author":"F Namour","year":"2018","unstructured":"Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol. 2018;84:2779\u201389. https:\/\/doi.org\/10.1111\/bcp.13726.","journal-title":"Br J Clin Pharmacol"},{"key":"1129_CR27","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3899\/jrheum.201183","volume":"48","author":"A Kavanaugh","year":"2021","unstructured":"Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48:1230\u20138. https:\/\/doi.org\/10.3899\/jrheum.201183.","journal-title":"J Rheumatol"},{"key":"1129_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1902617","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Mod Rheumatol. 2022;32:1\u201311. https:\/\/doi.org\/10.1080\/14397595.2021.1902617.","journal-title":"Mod Rheumatol."},{"issue":"Suppl 2","key":"1129_CR29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/annrheumdis-2015-eular.4457","volume":"74","author":"F Namour","year":"2015","unstructured":"Namour F, Vayssiere B, Galien R, Fagard L, Van der Aa A, Harrison P, et al. Filgotinib (GLPG0634), a selective JAK1 inhibitor, shows similar PK and PD profiles in Japanese and Caucasian healthy volunteers. Ann Rheum Dis. 2015;74(Suppl 2):1063\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1129_CR30","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1124\/dmd.106.009381","volume":"34","author":"T Imai","year":"2006","unstructured":"Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos. 2006;34:1734\u201341. https:\/\/doi.org\/10.1124\/dmd.106.009381.","journal-title":"Drug Metab Dispos"},{"key":"1129_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13152","author":"CH Hseuh","year":"2021","unstructured":"Hsueh C-H, Anderson K, Shen G, Yun C, Qin A, Othman AA. Evaluation of the potential drug interactions mediated through P-gp, OCT2 and MATE1\/2K with filgotinib in healthy subjects. Clin Trans Sci. 2022;15:361\u201370. https:\/\/doi.org\/10.1111\/cts.13152.","journal-title":"Clin Trans Sci."},{"key":"1129_CR32","doi-asserted-by":"publisher","unstructured":"Anderson K, Nelson CH, Gong Q, Alani M, Tarnowski T, Othman AA. Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants. Clin Pharmacol Drug Dev. 2022;11:235\u201345. https:\/\/doi.org\/10.1002\/cpdd.1015.","DOI":"10.1002\/cpdd.1015"},{"key":"1129_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/17425255.2019.1588884","volume":"15","author":"ACS Barbosa","year":"2019","unstructured":"Barbosa ACS, Feng Y, Yu C, Huang M, Xie W. Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases. Expert Opin Drug Metab Toxicol. 2019;15:329\u201339. https:\/\/doi.org\/10.1080\/17425255.2019.1588884.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1129_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nm1184","volume":"11","author":"MH Tong","year":"2005","unstructured":"Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med. 2005;11:153\u20139. https:\/\/doi.org\/10.1038\/nm1184.","journal-title":"Nat Med"},{"key":"1129_CR35","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/cpdd.870","volume":"10","author":"R Begley","year":"2020","unstructured":"Begley R, Anderson K, Watkins TR, Weng W, Ampaw L, Qin A, et al. Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel\/ethinyl estradiol in healthy volunteers. Clin Pharmacol Drug Dev. 2020;10:376\u201383. https:\/\/doi.org\/10.1002\/cpdd.870.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1129_CR36","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","volume":"76","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009\u201319. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210105.","journal-title":"Ann Rheum Dis"},{"key":"1129_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","volume":"76","author":"R Westhovens","year":"2017","unstructured":"Westhovens R, Taylor PC, Alten R, Pavlova D, Enr\u00edquez-Sosa F, Mazur M, et al. Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998\u20131008. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210104.","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01129-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01129-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01129-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T17:27:50Z","timestamp":1656696470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01129-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1129"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01129-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"10 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Florence Namour is an employee of Galapagos SASU. Kacey Anderson and Cara Nelson are former employees of Gilead Sciences, Inc., and hold stock in the company. Chantal Tasset is an employee of Galapagos NV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data on file in this manuscript are not available for sharing per current Galapagos guidelines; other included data have been published previously as cited.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Florence Namour, Kacey Anderson, and Cara Nelson were involved in the manuscript conceptualization and design as well as the acquisition, analysis and interpretation of the study data discussed herein. Chantal Tasset provided project overview and interpretation of the study data discussed herein. All authors contributed to manuscript development and provided their approval to submit.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}